1. Home
  2. ERAS vs SIFY Comparison

ERAS vs SIFY Comparison

Compare ERAS & SIFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • SIFY
  • Stock Information
  • Founded
  • ERAS 2018
  • SIFY 1995
  • Country
  • ERAS United States
  • SIFY India
  • Employees
  • ERAS N/A
  • SIFY N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • SIFY Computer Software: Programming Data Processing
  • Sector
  • ERAS Health Care
  • SIFY Technology
  • Exchange
  • ERAS Nasdaq
  • SIFY Nasdaq
  • Market Cap
  • ERAS 348.4M
  • SIFY 369.1M
  • IPO Year
  • ERAS 2021
  • SIFY 1999
  • Fundamental
  • Price
  • ERAS $1.45
  • SIFY $4.79
  • Analyst Decision
  • ERAS Strong Buy
  • SIFY
  • Analyst Count
  • ERAS 6
  • SIFY 0
  • Target Price
  • ERAS $4.83
  • SIFY N/A
  • AVG Volume (30 Days)
  • ERAS 1.2M
  • SIFY 33.9K
  • Earning Date
  • ERAS 08-11-2025
  • SIFY 07-18-2025
  • Dividend Yield
  • ERAS N/A
  • SIFY N/A
  • EPS Growth
  • ERAS N/A
  • SIFY N/A
  • EPS
  • ERAS N/A
  • SIFY N/A
  • Revenue
  • ERAS N/A
  • SIFY $466,789,000.00
  • Revenue This Year
  • ERAS N/A
  • SIFY N/A
  • Revenue Next Year
  • ERAS N/A
  • SIFY $13.46
  • P/E Ratio
  • ERAS N/A
  • SIFY N/A
  • Revenue Growth
  • ERAS N/A
  • SIFY 11.93
  • 52 Week Low
  • ERAS $1.01
  • SIFY $1.84
  • 52 Week High
  • ERAS $3.45
  • SIFY $5.71
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 52.19
  • SIFY 55.97
  • Support Level
  • ERAS $1.38
  • SIFY $4.55
  • Resistance Level
  • ERAS $1.58
  • SIFY $4.88
  • Average True Range (ATR)
  • ERAS 0.11
  • SIFY 0.22
  • MACD
  • ERAS 0.01
  • SIFY 0.03
  • Stochastic Oscillator
  • ERAS 64.86
  • SIFY 87.67

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About SIFY Sify Technologies Limited

Sify Technologies Ltd is a provider of corporate network services in India. It offers converged Information and Communication Technology (ICT) solutions comprising Network- Connectivity services, Data Center services and Digital Services which include Cloud and Managed services, Applications Integration services and Technology Integration services. The company operates in three segments; Network Connectivity services which consists of domestic data, international data, wholesale voice. Data Center Services which consists of co-location services, cross connects and other allied managed services. Digital Services which consists of Cloud and Managed Services, Network Managed Services, Applications Integration Services, Technology Integration Services. Key revenue is from Network.

Share on Social Networks: